Spironolactone and Gabapentin Interaction: Safety, Risks, and Clinical Guidance

What each drug is, so the pairing isn't confused with something else

Spironolactone (brand name Aldactone) works as a mineralocorticoid receptor antagonist and potassium-sparing diuretic. While FDA approval covers heart failure, hypertension, and edema, dermatologists commonly prescribe it off-label at doses ranging from 50 to 200 mg daily to treat hormonal acne and excess facial hair in women [1][3].

Gabapentin (brand names Neurontin and Gralise) is an anticonvulsant structurally related to GABA but not acting on GABA receptors. It is FDA-approved for postherpetic neuralgia and as adjunct therapy for partial seizures, and is used off-label for neuropathic pain, anxiety, and migraine prophylaxis at doses generally ranging from 300 mg to 3,600 mg daily [2][6].

These two drugs are sometimes confused in interaction checkers with sibling compounds (eplerenone for spironolactone, pregabalin for gabapentin). This article addresses spironolactone and gabapentin specifically.

The direct answer

Spironolactone and gabapentin do not share a metabolic pathway. Spironolactone is metabolized hepatically, largely through CYP3A4 and flavin-containing monooxygenase enzymes, into active metabolites such as canrenone [1]. Gabapentin undergoes no hepatic metabolism at all; it is absorbed through an intestinal amino acid transporter and excreted unchanged by the kidneys [2]. Because neither drug competes for the other's clearance pathway, there is no documented change in blood levels of either drug when they are taken together. The clinically relevant overlaps instead come from pharmacodynamics (both drugs can cause dizziness and drowsiness) and from organ function (gabapentin clearance depends on kidneys that spironolactone can affect). A dedicated pharmacokinetic or outcomes study of this specific drug pair was not identified in the sources used for this article, so the risk framing below is built from each drug's individual profile rather than combination-specific trial data.

The useful clinical question is not whether spironolactone and gabapentin interact directly. It is whether either drug's known off-target effect, sedation from gabapentin or a hemodynamic dip in kidney filtration from spironolactone, crosses a threshold that matters for a particular patient's age, baseline kidney function, and other medications.

Why the kidney matters more than the liver here

Gabapentin depends almost entirely on glomerular filtration for elimination, which is why the FDA label specifies lower doses at reduced creatinine clearance [2]. As kidney function declines, gabapentin accumulates and its sedating effects can intensify even without any change in the prescribed dose.

Spironolactone blocks aldosterone at the distal nephron. This reduces sodium reabsorption and potassium excretion, and it can also reduce renal plasma flow, producing a measurable early dip in estimated glomerular filtration rate (eGFR) in some patients after starting therapy. This hemodynamic dip is a recognized class effect of mineralocorticoid receptor antagonists, and has been studied in cohorts initiating these drugs, though the exact magnitude and recovery pattern vary by population and should be confirmed against the primary literature rather than assumed to be a fixed number for every patient [5]. In patients with normal baseline kidney function this dip is usually modest and often partially reverses with continued therapy; in patients with pre-existing chronic kidney disease, heart failure, or volume depletion, the effect can be more pronounced.

If spironolactone lowers a patient's eGFR enough to cross a renal dosing threshold, gabapentin clearance can fall as a downstream consequence. That is not a direct drug-drug interaction in the pharmacokinetic sense; it is an interaction mediated by organ function, and it is the reason kidney monitoring is the practical safeguard for this combination rather than a dose adjustment formula applied automatically.

Evidence-status interaction assessment: spironolactone + gabapentin

Could the combination make dizziness or drowsiness worse?

In gabapentin's pivotal trials for postherpetic neuralgia, dizziness and somnolence were among the most common adverse effects reported, listed at meaningfully higher rates than placebo [2]. Spironolactone's label also lists dizziness and drowsiness as recognized adverse reactions, though most of that safety data comes from heart failure and hypertension populations rather than the younger, generally healthier group treated for acne [1].

Gabapentin's sedating effect works through binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing neurotransmitter release [6]. Spironolactone's contribution to dizziness is thought to relate to mild blood pressure lowering and electrolyte shifts rather than a central sedative mechanism. Because the two drugs reach a similar symptom (dizziness or drowsiness) through different pathways, their effects can be additive in an individual patient, even though no controlled trial has quantified how often that happens for this specific pair. Clinical pharmacology references such as Lexicomp classify the combination as a monitor-level interaction rather than a contraindication, which reflects the absence of a metabolic conflict rather than an absence of clinical relevance. A low severity rating on an interaction checker means the combination is generally usable with attention, not that it carries no risk.

Alcohol is a practical amplifier worth naming directly: both drug labels warn against combining either medication with alcohol because of additive central nervous system depression. A patient on both drugs who drinks alcohol may notice more pronounced lightheadedness than either drug produces alone.

Does gabapentin affect potassium the way spironolactone does?

No. Gabapentin has no known effect on potassium homeostasis. Spironolactone, by contrast, is one of the more potent potassium-retaining drugs in routine use because it blocks aldosterone's effect on potassium excretion.

In heart failure populations, where spironolactone is used at doses similar to or higher than acne dosing and in patients with more comorbidity, the RALES trial (N=1,663) demonstrated a mortality benefit but required regular potassium monitoring throughout the study because of hyperkalemia risk, particularly in patients also taking ACE inhibitors [7]. That population differs substantially from a typical acne patient in age, baseline kidney function, and concurrent medications, so heart failure hyperkalemia rates should not be assumed to transfer directly to a healthy young woman on spironolactone for acne.

In the acne and hirsutism population specifically, a retrospective study of 974 women aged 18 to 45 treated with spironolactone found a low rate of hyperkalemia, under one percent of the cohort, in patients without pre-existing renal disease [8]. This is the basis for the widely cited clinical position that routine potassium monitoring may not be necessary for every healthy young woman on spironolactone for acne, though the decision to monitor should still account for individual risk factors such as kidney disease, heart disease, or concurrent ACE inhibitor or ARB use, and should follow current dermatology guideline language rather than this article [9].

Gabapentin does not add to potassium risk directly. It becomes relevant only through the renal pathway described above: if spironolactone lowers eGFR enough to matter, that same decline can worsen both potassium retention and gabapentin accumulation at once, which is why a single monitoring panel, creatinine, eGFR, and potassium, covers both concerns.

How is the combination usually started in practice?

Prescribers commonly start one drug at a time so any new symptom can be attributed to the newer medication. If spironolactone is already established, gabapentin is typically started at a low dose and titrated gradually per the FDA label, often dosed at night to take advantage of its sedating effect rather than have it interfere with daytime activity [2]. If gabapentin is already established, spironolactone is typically started at a low dose and titrated upward over weeks, with a basic metabolic panel checked before starting and again after a few weeks of co-therapy.

Advising patients to rise slowly from sitting or lying positions during the first couple of weeks of overlap is a simple, low-cost step that addresses the orthostatic and sedative overlap directly. Specific starting doses, titration schedules, and renal dose adjustments should come from the prescribing clinician based on the patient's actual kidney function and other medications, not from a general guide.

Who should be more cautious with this combination?

Older adults. The 2023 American Geriatrics Society Beers Criteria identifies gabapentin as a medication to use with caution in adults 65 and older because of fall risk related to central nervous system effects [10]. Adding spironolactone's orthostatic potential to that baseline risk is a reasonable concern, and closer monitoring of balance, dizziness, and orthostatic vital signs is warranted in this group.

Patients on ACE inhibitors or ARBs. Combining an ACE inhibitor or ARB with spironolactone independently raises hyperkalemia risk, separate from gabapentin. Gabapentin does not add to potassium risk directly, but if kidney function declines because of the ACE inhibitor and spironolactone combination, gabapentin clearance can fall as a secondary consequence, which is a reason for closer laboratory follow-up in patients on all three drugs together.

Chronic kidney disease. Both the gabapentin FDA label and standard nephrology practice call for dose adjustment once eGFR falls below 60 mL/min/1.73 m² [2]. If spironolactone is contributing to that decline, the prescriber and patient need to weigh whether the acne or hirsutism benefit still justifies continuing spironolactone, or whether an alternative approach makes more sense.

When should the combination be reassessed, or urgent care sought?

Contact the prescribing clinician if any of the following occur:

• New or worsening dizziness, drowsiness, or unsteadiness that interferes with daily activity, especially in the first two to four weeks after starting the second drug
• Repeated falls or fainting
• Laboratory results showing a meaningful rise in potassium or a meaningful drop in eGFR compared with baseline
• Swelling, palpitations, muscle weakness, or confusion, which can signal significant hyperkalemia and warrant urgent evaluation

These are general warning signs based on each drug's known adverse effect profile, not a validated combination-specific alert threshold, since no such threshold has been established in the sources reviewed for this article.

Alternatives worth discussing with a prescriber

For acne or hirsutism, alternatives that avoid spironolactone's renal and potassium effects include topical clascoterone 1% cream (Winlevi), FDA-approved in 2020 for acne in patients aged 12 and older, which acts locally at the hair follicle and sebaceous gland without the systemic mineralocorticoid effects of oral spironolactone [11]. Combined oral contraceptives containing antiandrogenic progestins are another established option for women who are candidates for hormonal contraception, though this option carries its own considerations that a prescriber should discuss individually.

What the evidence actually establishes, and what it does not

Established: Spironolactone and gabapentin do not share a liver enzyme or transporter pathway, so there is no documented pharmacokinetic interaction. Both drugs individually list dizziness and drowsiness as adverse effects. Gabapentin clearance depends on kidney function. Spironolactone can lower kidney filtration through its mechanism of action.

Plausible but not directly tested for this pair: That the combination produces more dizziness or drowsiness together than either drug alone, and that a spironolactone-related dip in kidney function could raise gabapentin levels enough to be noticeable. Both follow logically from established single-drug pharmacology, but neither has been measured in a study of the combination itself.

Not established: Any specific incidence rate of dizziness, falls, or hyperkalemia attributable to this combination as opposed to either drug alone. No dedicated interaction trial or population-level safety study of spironolactone plus gabapentin was identified for this article.

Bottom line

Spironolactone and gabapentin do not interact through liver metabolism or transporters. The two overlaps that matter in practice are additive sedation, manageable with careful dose timing and slow titration, and an indirect renal link, managed with baseline and follow-up kidney and potassium testing. For a younger, otherwise healthy person taking spironolactone for acne at typical doses, the practical risk of adding gabapentin is generally considered low by clinicians, but that judgment should come from the prescribing clinician based on individual kidney function, age, and other medications, not from a general reference article.